Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336018 · ClinicalTrials.gov registry record · Phase 1
A Research Study on Etavopivat in Participants With and Without Liver Disease
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06336018 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 48 participants.
The verdict
NCT06336018, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.
Interventions
- DRUG Etavopivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336018
The ClinicalTrials.gov registry entry for NCT06336018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etavopivat is the first listed.
NCT06336018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06336018 about?
NCT06336018 is a clinical study titled "A Research Study on Etavopivat in Participants With and Without Liver Disease". The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat ora...
What is the current status of trial NCT06336018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-05-20. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT06336018?
The interventions under investigation include: Etavopivat (DRUG).
Who is sponsoring clinical trial NCT06336018?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.